Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)

The report reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects

The report assesses Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Aptevo Therapeutics Inc

Astellas Pharma Inc.

Astex Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

Cyclacel Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Innate Pharma S.A.

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

LFB S.A.

Lymphocyte Activation Technologies, S.A.

Millennium Pharmaceuticals Inc

MorphoSys AG

Novartis AG

Oncternal Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd.

PIQUR Therapeutics AG

Rhizen Pharmaceuticals S.A.

Sanofi

TRACON Pharmaceuticals Inc

Tragara Pharmaceuticals, Inc.

Verastem, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8

Therapeutics Development 9

Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9

Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10

Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11

Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17

Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20

Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21

4SC AG 21

AbbVie Inc 22

Aptevo Therapeutics Inc 23

Astellas Pharma Inc. 24

Astex Pharmaceuticals Inc 25

Boehringer Ingelheim GmbH 26

Bristol-Myers Squibb Company 27

Celgene Corporation 28

Cellular Biomedicine Group, Inc. 29

Cyclacel Pharmaceuticals, Inc. 30

F. Hoffmann-La Roche Ltd. 31

Gilead Sciences, Inc. 32

Hutchison MediPharma Limited 33

ImmunoGen, Inc. 34

Immunomedics, Inc. 35

Incyte Corporation 36

Innate Pharma S.A. 37

Juno Therapeutics Inc. 38

Karyopharm Therapeutics, Inc. 39

LFB S.A. 40

Lymphocyte Activation Technologies, S.A. 41

Millennium Pharmaceuticals Inc 42

MorphoSys AG 43

Novartis AG 44

Oncternal Therapeutics, Inc. 45

Ono Pharmaceutical Co., Ltd. 46

PIQUR Therapeutics AG 47

Rhizen Pharmaceuticals S.A. 48

Sanofi 49

TRACON Pharmaceuticals Inc 50

Tragara Pharmaceuticals, Inc. 51

Verastem, Inc. 52

Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 53

Assessment by Monotherapy Products 53

Assessment by Combination Products 54

Assessment by Target 55

Assessment by Mechanism of Action 58

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

(dezapelisib + itacitinib adipate) - Drug Profile 65

4SC-202 - Drug Profile 66

acalabrutinib - Drug Profile 68

ACP-319 - Drug Profile 71

afuresertib hydrochloride - Drug Profile 72

AGS-67E - Drug Profile 75

AT-7519 - Drug Profile 77

atezolizumab - Drug Profile 80

BI-836826 - Drug Profile 94

BMS-986016 - Drug Profile 96

buparlisib hydrochloride - Drug Profile 98

CBM-C19.1 - Drug Profile 103

CC-122 - Drug Profile 104

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 106

Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 107

duvelisib - Drug Profile 108

HMPL-523 - Drug Profile 119

idelalisib - Drug Profile 121

IMGN-529 - Drug Profile 129

IMMU-114 - Drug Profile 131

JCAR-014 - Drug Profile 133

JCAR-015 - Drug Profile 136

lirilumab - Drug Profile 141

monalizumab - Drug Profile 145

MOR-208 - Drug Profile 148

nivolumab - Drug Profile 153

obinutuzumab - Drug Profile 182

ofatumumab - Drug Profile 189

otlertuzumab - Drug Profile 197

PCAR-019 - Drug Profile 200

PCAR-119 - Drug Profile 201

pilaralisib - Drug Profile 202

PNK-007 - Drug Profile 204

PQR-309 - Drug Profile 205

S-055746 - Drug Profile 207

sapacitabine - Drug Profile 208

selinexor - Drug Profile 214

spebrutinib besylate - Drug Profile 233

TAK-659 - Drug Profile 235

TG-02 - Drug Profile 236

TGR-1202 - Drug Profile 239

tisagenlecleucel-T - Drug Profile 246

TRC-102 - Drug Profile 251

ublituximab - Drug Profile 253

UC-961 - Drug Profile 260

ulocuplumab - Drug Profile 262

urelumab - Drug Profile 263

venetoclax - Drug Profile 265

Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 274

Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 276

Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 277

Featured News & Press Releases 277

Appendix 289

Methodology 289

Coverage 289

Secondary Research 289

Primary Research 289

Expert Panel Validation 289

Contact Us 289

Disclaimer 290

List of Tables

List of Tables

Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2016 13

Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H2 2016 24

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by 4SC AG, H2 2016 25

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by AbbVie Inc, H2 2016 26

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aptevo Therapeutics Inc, H2 2016 27

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astellas Pharma Inc., H2 2016 28

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astex Pharmaceuticals Inc, H2 2016 29

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 30

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bristol-Myers Squibb Company, H2 2016 31

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Celgene Corporation, H2 2016 32

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 33

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 34

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 35

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Gilead Sciences, Inc., H2 2016 36

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Hutchison MediPharma Limited, H2 2016 37

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by ImmunoGen, Inc., H2 2016 38

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Immunomedics, Inc., H2 2016 39

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Incyte Corporation, H2 2016 40

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Innate Pharma S.A., H2 2016 41

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Juno Therapeutics Inc., H2 2016 42

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 43

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by LFB S.A., H2 2016 44

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016 45

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 46

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by MorphoSys AG, H2 2016 47

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Novartis AG, H2 2016 48

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Oncternal Therapeutics, Inc., H2 2016 49

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 50

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by PIQUR Therapeutics AG, H2 2016 51

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 52

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sanofi, H2 2016 53

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 54

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 55

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline by Verastem, Inc., H2 2016 56

Assessment by Monotherapy Products, H2 2016 57

Assessment by Combination Products, H2 2016 58

Number of Products by Stage and Target, H2 2016 60

Number of Products by Stage and Mechanism of Action, H2 2016 63

Number of Products by Stage and Route of Administration, H2 2016 66

Number of Products by Stage and Molecule Type, H2 2016 68

Relapsed Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H2 2016 278

Relapsed Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..1), H2 2016 279

Relapsed Chronic Lymphocytic Leukemia (CLL) – Discontinued Products, H2 2016 280

List of Figures

List of Figures

Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2016 13

Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Assessment by Monotherapy Products, H2 2016 57

Number of Products by Top 10 Targets, H2 2016 59

Number of Products by Stage and Top 10 Targets, H2 2016 59

Number of Products by Top 10 Mechanism of Actions, H2 2016 62

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 62

Number of Products by Routes of Administration, H2 2016 65

Number of Products by Stage and Routes of Administration, H2 2016 65

Number of Products by Molecule Types, H2 2016 67

Number of Products by Stage and Molecule Types, H2 2016 67

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports